Market capitalization | $95.81m |
Enterprise Value | $-57.35m |
P/E (TTM) P/E ratio | 4.62 |
EV/FCF (TTM) EV/FCF | 43.45 |
P/B ratio (TTM) P/B ratio | 0.54 |
Revenue growth (TTM) Revenue growth | -100.00% |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-12.87m |
Free Cash Flow (TTM) Free Cash Flow | $-1.32m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
1 Analyst has issued a forecast Oramed Pharmaceuticals Inc.:
1 Analyst has issued a forecast Oramed Pharmaceuticals Inc.:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.22 -0.22 |
-
|
|
EBITDA | -13 -13 |
53%
53%
|
EBIT (Operating Income) EBIT | -13 -13 |
52%
52%
|
Net Profit | 21 21 |
203%
203%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It focuses in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in Jerusalem, Israel.
Head office | United States |
CEO | Nadav Kidron |
Employees | 15 |
Founded | 2002 |
Website | www.oramed.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.